From a theranostic perspective, our results suggest that developing immuno-PET agents using ADCC-enhanced tumor-targeting IgG1 antibodies may yield false-positive results in lymph nodes because of Fc–FcγR interactions in vivo. Here, FCGR2A is linked to neoplasm.